Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.

@article{Ray2003ApoptosisII,
  title={Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.},
  author={Subrata Kumar Ray and Alex Almasan},
  journal={Cancer research},
  year={2003},
  volume={63 15},
  pages={4713-23}
}
Because apoptosis is deregulated in most cancers, apoptosis-modulating approaches offer an attractive opportunity for clinical therapy of many tumors, including that of the prostate. LNCaP-derived C4-2 human prostate cancer cells are quite resistant to treatment with Apo2 ligand (Apo2L) or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), when using a nontagged, Zn-bound recombinant trimeric version that is devoid of any exogeneous sequences and therefore least likely to be… CONTINUE READING
30 Extracted Citations
70 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 30 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 70 references

Combined effect of tumor necrosis factor4722 Apo2L/TRAIL THERAPY IN PROSTATE CANCER

  • A. M. Chinnaiyan, U. Prasad, +5 authors A. Rehemtulla
  • Research. on August
  • 2003
2 Excerpts

Similar Papers

Loading similar papers…